Clinical trialNCT00283712CompletedPhase 2Interventional

Use of Infliximab for the Treatment of Pemphigus Vulgaris

SponsorNational Institute of Allergy and Infectious Diseases (NIAID)Enrollment20Pemphigus

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Pemphigus vulgaris (PV) is a rare skin disorder that causes blistering of the skin and mucous membranes. Infliximab is a man-made antibody used to treat certain types of immune system disorders, including rheumatoid arthritis and Crohn's disease. This study will determine if infliximab given in combination with prednisone is a safe and effective treatment for adults with PV.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

David Woodley, MD
Department of Dermatology, Norris Cancer Center, University of Southern California
Principal Investigator
clinicaltrials.gov ↗
E. William St. Clair, MD
Division of Rheumatology and Immunology, Duke University Medical Center
Study Chair
clinicaltrials.gov ↗
Garnett Kelsoe, DSci
Department of Immunology, Duke University
Principal Investigator
clinicaltrials.gov ↗
Janet Fairley, MD
Department of Dermatology, University of Iowa
Principal Investigator
clinicaltrials.gov ↗
Russell P. Hall, MD
Division of Dermatology, Duke University Medical Center
Study Chair
clinicaltrials.gov ↗
Victoria Werth, MD
Department of Dermatology, University of Pennsylvania School of Medicine
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Norris Cancer Center, University of Southern California
Los Angeles, California, United States
University of Iowa Hospitals and Clinics
Iowa City, Iowa, United States
Duke University Medical Center
Durham, North Carolina, United States
University of Pennsylvania
Philadelphia, Pennsylvania, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Infliximab →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Mar 2006
Primary completion: 31 Dec 2010
Completion: 31 Mar 2011
Last update posted: 6 Dec 2017
Registered enrollment: 20
Registry id: NCT00283712

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.